Bao Yueyang, Lee John, Thakur Udit, Ramkumar Satish, Marwick Thomas H
School of Medicine, University of Tasmania, Hobart, TAS, Australia.
Department of Cardiology, Royal Hobart Hospital, Hobart, TAS, Australia.
Cardiooncology. 2023 Jun 17;9(1):29. doi: 10.1186/s40959-023-00180-3.
Atrial fibrillation (AF) is a common cardiac complication during cancer treatment. It is unclear if cancer survivors have increased AF risk when compared to the population. AF screening is now recommended in patients ≥65 years, however there are no specific recommendations in the oncology population. We sought to compare the AF detection rate of cancer survivors compared to the general population.
We searched the Pubmed, Embase and Web of Science databases using search terms related to AF and cancer mapped to subject headings. We included English language studies, limited to adults > 18 years who were > 12 months post completion of cancer treatment. Using a random-effects model we calculated the overall AF detection rate. Meta-regression analysis was performed to assess for potential causes for study heterogeneity.
Sixteen studies were included in the study. The combined AF detection rate amongst all the studies was 4.7% (95% C.I 4.0-5.4%), which equated to a combined annualised AF rate of 0.7% (95% C.I 0.1-0.98%). There was significant heterogeneity between studies (I = 99.8%, p < 0.001). In the breast cancer cohort (n = 6 studies), the combined annualised AF rate was 0.9% (95% C.I 0.1-2.3%), with significant heterogeneity (I = 99.9%, p < 0.001).
Whilst the results should be interpreted with caution due to study heterogeneity, AF rates in patients with cancer survival >12 months were not significantly increased compared to the general population.
Open Science Framework - DOI: https://doi.org/10.17605/OSF.IO/APSYG .
心房颤动（AF）是癌症治疗期间常见的心脏并发症。与普通人群相比，癌症幸存者的房颤风险是否增加尚不清楚。目前建议对65岁及以上患者进行房颤筛查，但肿瘤患者群体尚无具体建议。我们试图比较癌症幸存者与普通人群的房颤检出率。
我们使用与房颤和癌症相关的检索词在PubMed、Embase和Web of Science数据库中进行检索，并映射到主题词。我们纳入了英文研究，限于癌症治疗完成后12个月以上的18岁以上成年人。使用随机效应模型计算总体房颤检出率。进行Meta回归分析以评估研究异质性的潜在原因。
该研究纳入了16项研究。所有研究的合并房颤检出率为4.7%（95%置信区间4.0-5.4%），相当于年化房颤合并率为0.7%（95%置信区间0.1-0.98%）。研究之间存在显著异质性（I=99.8%，p<0.001）。在乳腺癌队列（n=6项研究）中，年化房颤合并率为0.9%（95%置信区间0.1-2.3%），存在显著异质性（I=99.9%，p<0.001）。
尽管由于研究异质性，结果应谨慎解释，但与普通人群相比，癌症存活超过12个月患者的房颤发生率并未显著增加。
开放科学框架 - DOI：https://doi.org/10.17605/OSF.IO/APSYG 。
